Atypical HUS – RESOURCES
About aHUS – General Info
Image Gallery: Atypical HUS info & advocacy
Atypical HUS 1.0 – to ‘QuickStart’ your search for Info & Resources
aHUS Community Advisory Board (CAB)
2022 Atypical HUS Therapeutic Drugs – a Landscape Overview https://bit.ly/aHUS2022drugReview
Special Events – held Annually
aHUS Awareness Day (24 Sept) & Rare Disease Day – Info & Resources. Links to our current Campaigns
See our Campaigns on Twitter: @aHUS24Sept & @aHUSallianceAct
2022 SEPT 2023 – FACT SHEET (released for 24 Sept: aHUS Awareness Day)
Clinical Information
Genetic Atypical Hemolytic-Uremic Syndrome – GeneReviews®
KDIGO Conclusions from a “Kidney Disease: Improving Global Outcomes” for aHUS and C3 Glomerulopathy
KDIGO: aHUS & C3G Physician Reference Guide
Atypical HUS Clinical Channel (YouTube)
aHUS Research & Publications: a Clinical ‘Library’
Networks and Support
Nations: aHUS Advocacy & Patient Groups (for Articles on specific nations, see below: Patient Engagement & Experience)
aHUS Clinicians & Investigators
Global aHUS Community Advisory Board (CAB) Visit Our aHUS CAB Landing Page https://bit.ly/GlobalCABaHUS
aHUS Global Advocate: NEWSLETTER
aHUS NEWSLETTER (Intro & Subscription Info): aHUS Alliance Launches its Newsletter
aHUS Global Advocate Newsletters: Archived Volumes
Vol 6 Newsletter (Jan 2023)
Newsletter Special Edition: Report #2 onFindings from 2021 aHUS Global Survey (Dec 2021)
Vol 5 Newsletter (Oct 2021)
1st Anniversary Edition Vol 4 Newsletter (June 2021)
Vol 3 Newsletter (Dec 2020)
Vol 2 Newsletter (Aug 2020)
INAUGURAL Edition – aHUS Allliance Action Newsletter 1 (July 2020)
aHUS alliance Global Action – our own Research
2021 aHUS Global Survey: BACKGROUND Article
1st Report (issued 24 Sept 2021) Article w/ Background REPORT 1 (pdf): Patients’ experience and perception of the aHUS diagnostic process
2nd Report (issued 18 Dec 2021) – Article w/ Background REPORT 2 (pdf): From Patients’ 1st Symptoms, with Escalation to Specialist Care
3rd Report (issued 28 Feb 2022) Article w/ Background REPORT 3 (pdf) Patients’ experience of Specialist Care: the Diagnosis Decisions
4th Report (issued 10 June 2022) Article w/ Background REPORT 4 (pdf) Impact of process event and patient
demographic variables on process outcomes
Poll QUESTIONS: Click HERE to View the 2021 aHUS Diagnostic Survey tool
Comparison of Experiences and Expectations of Ravulizumab
Note: This page contains a PARTIAL LISTING of articles available on
the aHUS Alliance Global Action website: Use our SEARCH BAR.
aHUS & COVID-19: Articles, Information, Resources
COVID Triggers aHUS: 15 Publications (1 March 2022)
COVID 19 Triggers aHUS (12 July 2021)
aHUS Alliance: COVID-19 Info Page
Webinar: aHUS & COVID-19 (24 Apr 2020) Global Registry SAB presents aHUS Patient FAQs
Webinar Transcript (24 Apr 2020) Written Transcript of the above)
aHUS & COVID-19: A Resource Page Information, Research, News of interest to the aHUS community. Articles on New Info regarding COVID-19 appeared: 17 April 2020, COVID-19 Update and 30 April 2020 Atypical HUS & COVID-19
aHUS & COVID-19 Vaccination (articles)
aHUS and COVID-19 Vaccine Update
aHUS and COVID-19 Vaccinations
ARTICLES on the topic of COVID-19
Like an Agatha Christie Story! (13 Aug 2020) A look at COVID-19 & complement over-activation
Reflections on aHUS during a Global Pandemic (7 May 2020) A holistic view of patient advocacy
aHUS and COVID-19 (18 Mar 2020) Conversations and Insights
They “Get It’ When they can Get It (14 Mar 2020) Parallels among COVID-19 & Rare Diseases
aHUS Trials Watch 10 (8 March 2020) Toronto Complement Conference, NCT04288713, and COVID-19
Thrombotic Microangiopathy & Precision Medicine What’s to be learned from the Pandemic?
COVID-19: Challenges faced by Dialysis Patients Patient Concernss & Issues for Dialysis Centers
Mental Health & COVID-19 Mental Heath: Issues & Resources
Patient Experiences & Engagement
aHUS global Town Hall – a virtual mtg for aHUS Day 2022
Launch of a global aHUS Community Advisory Board (CAB)
It’s Time to Re-Define aHUS Patient Engagement
The Final aHUS Awareness Day? (as classification & terminology change)
The Light & Dark World of aHUS
Answers to aHUS Questions (common FAQs for families to avoid misinformation)
Eculizumab aHUS Treatment: PESaM
Experiencing aHUS – Viewpoints & Variations
aHUS Health, Well Being, and Work
Patient Engagement: Reality or Buzzwords?
It’s not about My Rare Disease
A Reluctant Advocate (Book pdf)
NATIONAL GROUPS & aHUS Patients around the World
Living with aHUS: What would you Say?
aHUS in China (see also Are aHUS Patients in China Different? )
Samko & family: Tale from Slovakia
Learn about international advocacy via our global aHUS Community Advisory Board https://bit.ly/GlobalCABaHUS
Atypical HUS: Engagement
Atypical HUS: Not Like the Others
Collaborative Partnership in Research: Global aHUS Registry
aHUS Global Patients’ Research Agenda
Atypical HUS Perspectives A library of aHUS Alliance articles & interviews with Scientists, national aHUS advocacy Groups & aHUS Patients around the world.
Focus on Children & Young Adults
aHUS for Youth Leaders, Camps & Sports
Teen transitioning to Adult Nephrology Care
Parent Questions about Childhood aHUS Issues
EDU: Teaching & Learning at Work and School
international consensus, Management of aHUS in Children
Issue specific Topics
(Visit our Research Page for Lists of aHUS Research by Topic. Note: This is only a PARTIAL LISTING of articles available on the aHUS Alliance Global Action website: Use our site’s SEARCH BAR. See our separate lists below for Diagnosis, Patient Engagement, Treatment & Withdrawal, and More)
aHUS Adverse Events (AE) Reporting
aHUS & DGKε : One Genetic problem but Two Diseases
Thrombotic Microangiopathy: The Need for a Multidisciplinary Approach
Living with aHUS: What would you Say?
aHUS Nomenclature Project Goup
aHUS Relapse: Epilogue (last of 4 part series)
NICE: Evaluating Ravulizumab for aHUS (Drug access- Guidance, NHS in England & Wales)
Answers to aHUS Questions (common FAQs for families to avoid misinformation)
Dental Health & Kidney Disease
aHUS Webinar, by Dr Marina Noris
A Pillar of Hope (on aHUS/HUS/TMA Registries)
aHUS – Interpretation is Complex
Rare Disease Patients becoming Rarer in the USA
aHUS Relapse: 3 part Series (Part 1, Part 2, Part 3)
Again, How many aHUS Patients are There?
aHUS Health, Well Being, and Work
Anti-FH aHUS: a Disease within a Disease
2020 aHUS Therapeutic Drug Landscape: an Overview
aHUS Care: The Case for Multidisciplinary Collaboration
Infusions while Traveling Away from Home
Cardiorenal Syndrome: Heart & Kidney Relationship
EDU: Teaching & Learning at Work and School
Thrombotic Microangiopathy: TMA & aHUS
Complement-Mediated TMA Awareness – Did you Know it’s aHUS?
aHUS: A ‘Constellation of Symptoms’ (Dr A Chang)
Is it aHUS? Perhaps it’s TTO, STEC-HUS, or Another TMA
aHUS and TMA Syndromes Consensus
Thrombotic Microangiopathy: Through the Lens of aHUS (article) (TMA Boston Symposium: 9 Videos)
aHUS Diagnosis
aHUS Diagnosis: 2021 Survey of Patient Experiences (4 Reports)
Study of the aHUS Diagnosis Process- the “whys”, “whats” and “hows”
Update: aHUS Diagnosis Process Study
aHUS “A Constellation of Symptoms”
aHUS Diagnosis: Time is of the Essence
The Challenge of aHUS Secondary Diagnosis
aHUS Diagnosis & Treatment: KDIGO Controversies Conference
Is it aHUS? Perhaps its TTP, STEC-HUS, or another TMA
Transplants & Dialysis
aHUS Kidney Transplants – More Insights
Transplant Research Answers that Matter to aHUS Patients
Dialysis Diaries (a 4 Part series): aHUS & Dialysis, Diets & Fluids, Heart Problems, Long Term Complications
aHUS & Dialysis: Lab-Grown Kidneys: Are We There Yet?
COVID-19 (see listing above)
aHUS Classification – Varied Terms & Nomenclature
aHUS Nomenclature Project Group
A Babble of Names: What type of aHUS?
aHUS – a Constellation of Symptoms
Complement-mediated TMA Awareness- Did you know it was aHUS?
TTP and aHUS: Different Diseases, but still Linked
A Rose by any Other Name – What’s the Fuss?
Advocacy
Atypical HUS Community Advisory Board – our aHUS CAB Landing Page https://bit.ly/GlobalCABaHUS
Join the aHUS CAB – How to become a Member (with application form)
Atypical HUS: Not Like the Others
How to become a rare disease Advocate for aHUS
aHUS Advocate at the United Nations, K Shah
Reluctant Advocate, series: Changing UK Health Policy
aHUS at the Cleveland Clinic Rare Genetic Disease Symposium
Whistlestop Tour- Patient Advocates at 4 Expert Centres
R.O.W. : aHUS in the Rest of the World
aHUS Conference: the Dutch Approach
aHUS Awareness Day & Rare Disease Day
Interviews
Kerri Grey – Meet the new Trustee of aHUS Alliance Global Action
Kamal D Shah – Founder of aHUS India, NephroPlus co-Founder, global aHUS CAB founding Member
Joana Preto – aHUS in Portugal
Dr Brad Lewis of Machaon Diagnostics: aHUS genetic testing
CUREiHUS &Radboud, NL: Drs N van de Kar, J Wetzels, C Duineveld & K Wijnsma
Prof Fadi Fakhouri: aHUS & Pregnancy
Dr Gianluigi Ardissino: Centro SEU
Drs M McCullogh & E Gottlich: Proposal for aHUS Drug Access
Dr Adrian Lungu: aHUS in Romania
Dr Ralf Reski: Moss-FH & biopharmaceuticals
Prof Stephen Perkins: Complement Database
Dr I-Ru Chen: Taiwan, China Times article for aHUS Day
Sarah Staffiere: Finding a New Normal after aHUS Diagnosis
Cameron James: Family Rhythms & aHUS
Kamal D. Shah: Patient & co-Founder NephroPlus Dialysis Centres
Patient materials & Resources
aHUS Fact & Info Sheets: 2022-Sept-2023 Edition 2020-Sept 2021 Edition Previous Yr: 2019 Edition
Info Center : aHUS materials in Spanish and in French, Info & Materials for aHUS Awareness Day & Rare Disease Day, results from global Polls & Patient Research Agenda , Press Kit aHUS Research – Organized by Topic
aHUS Symptoms can be Perplexing
aHUS Expert Centres, Attributes
ES: SHUa-Síndrome Hemolítico Urémico Atípico
FR: Syndrome Hémolytique et Urémique Atypique
Clinical trials & Drug R/D
Recruiting to aHUS Trials is Not Easy
aHUS Uncertainty is a Certainty
2020 aHUS Therapeutic Drug Landscape: an Overview
ClinicalTrials.gov Atypical HUS (trials)
ClinicalTrials.gov Thrombotic Microangiopathies (trials)
Breaking Down Barriers in aHUS Clinical Trials
Clinical Trial Watch – Articles
aHUS Trial Watch 17- NovelMed: NM8074
aHUS Trial Watch 16- BioCryst: Factor D BCX9930
aHUS Trial Watch 15 UPDATE- Iptacopan
aHUS Trial Watch 15- Iptacopan
aHUS Trial Watch 14- New Trial re Ravulizumab for TMA
aHUS Trial Watch 12A/ 13 (re Pediatric Trial posted for Crovalimab)
aHUS Trial Watch 12 (Crovalimab update)
aHUS Clinical Trials Watch 11 – Crovalizumab (Jan 2021)
aHUS Trials Watch 10 (8 March 2020) Toronto Complement Conference, NCT04288713, and COVID-19
Akari Therapeutics Coversin, NCT03829449
Alexion Eculizumab & Ravulizumab, formerly ALXN1210 (Spotlight 5, Series)
Clinical Trial, Stopping Eculizumab: STOPECU (NCT02574403)
Alnylam Cemdisiran Switching from Eculizumab to Cemdisiran, NCT03999840
Generium Eliziara, 1st biosimilar to Eculizumab
Omeros Narsoplimab UK Collaboration
Roche Crovalimab, NCT04861259
Samsung Bioepis Co. Ltd SB12- potential biosimilar to eculizumab
aHUS Drug R & D Therapeutics, 2018
Small Molecule Factor D Inhibitors
2020 aHUS Therapeutic Drug Overview
Drug Access & Treatment (see also Topic-Specific ISSUES)
aHUS Adverse Events & Patient Reported Outcomes
England recommends Ravulizumab for aHUS
Scotland approves Ravulizumab for aHUS
Evidence Helps aHUS Eculizumab Access
Global Drug Access Panel Proposal, South Africa
2020 aHUS Therapeutic Drug Landscape: an Overview
Challenges of Eculizumab: Patients’ Perspective (section, Raina et al. 2019)
aHUS Drug Access in Low Resource Nations, Dr A Bagga (Cleveland Clinic, Sept 2019)
2016 aHUS Global Poll data: White paper – Access to Treatment
2018 aHUS Therapeutic Drugs, Market Factors
Stopping Eculizumab: On Treatment Withdrawal
Decision Process: Discontinuing aHUS Treatment
Evidence Helps Eculizumab Access
Eculizumab Withdrawal – Safe & Reasonable?
Eculizumab Withdrawal Risk Profiling (Acosta Medina Group, re TMA at ASH20)
StopEcu: The French Study Reports
Withdrawal Evidence Patients Need to Know
aHUS “A Constellation of Symptoms”
Ravulizumab: Cost effectiveness & Patient Quality of Life
Ravulizumab is not quite Eculizumab
Eculizumab to Ravulizumab – Transfer/Switch Update
Ravulizumab Costs Less over a Lifetime
Is Ravulizumab Affordable for aHUS?
aHUS Community Answers the Call
Visit our Research Page for Lists of aHUS Research by Topic.
Note: This is only a PARTIAL LISTING of articles available on
the aHUS Alliance Global Action website: Use our SEARCH BAR.
Social Media & YouTube
Twitter: @aHUSAllianceAct and @aHUS24Sept (aHUS Awareness Day)
Atypical HUS Clinical Channel YouTube
Atypical HUS Patient Voice Channel YouTube
Info Centre: aHUS Social Media
National aHUS Patient Advocacy: Network
Your Nation not Listed? Learn about the R.O.W. (Rest of the World)
Connect with the aHUS Alliance Global Action Team
Contact us
info@aHUSallianceAction.org